Blincyto Global Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

Blincyto (blinatumomab) is a prescription drug used to treat certain types of blood cancers. It is a bispecific T-cell engager (BiTE) antibody construct that functions by connecting cancerous B cells with T cells, a type of immune cell. Blincyto works by harnessing the body's immune system to recognize and eliminate malignant B cells.

The types of Blincyto include prefilled and non-prefilled formulations. Prefilled Blincyto refers to a ready-to-use form in which the medication is supplied in preassembled syringes or vials, making preparation and administration more convenient. It is distributed through hospital pharmacies, retail pharmacies, and online pharmacies for the treatment of acute lymphoblastic leukemia and other hematological disorders. The medication is used in hospitals, clinics, and research institutions.

Tariffs have impacted the blincyto market by increasing costs for imported biologic raw materials, infusion delivery systems, and specialized manufacturing inputs. These cost pressures have influenced treatment affordability in oncology centers, particularly in regions dependent on imported biologics. Hospital pharmacy and specialty oncology segments in asia-pacific and latin america are among the most affected. Conversely, tariffs have encouraged regional biologics production, investment in advanced manufacturing, and long-term supply chain resilience for cancer immunotherapies.

The blincyto market research report is one of a series of new reports from The Business Research Company that provides blincyto market statistics, including blincyto industry global market size, regional shares, competitors with a blincyto market share, detailed blincyto market segments, market trends and opportunities, and any further data you may need to thrive in the blincyto industry. This blincyto market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The blincyto market size has grown strongly in recent years. It will grow from $0.81 million in 2025 to $0.86 million in 2026 at a compound annual growth rate (CAGR) of 6.1%. The growth in the historic period can be attributed to limitations of conventional chemotherapy, rising incidence of blood cancers, advancements in monoclonal antibody research, unmet needs in relapsed leukemia, hospital-based cancer treatment models.

The blincyto market size is expected to see strong growth in the next few years. It will grow to $1.08 million in 2030 at a compound annual growth rate (CAGR) of 5.8%. The growth in the forecast period can be attributed to growth in precision medicine adoption, increasing approvals for immunotherapies, expansion of specialty oncology centers, rising clinical trial activity, improved patient survival outcomes. Major trends in the forecast period include rising adoption of immuno-oncology therapies, growing use of bi-specific antibody treatments, expansion of targeted cancer immunotherapy, increased focus on minimal residual disease treatment, shift toward precision oncology approaches.

The rising incidence of leukemia is expected to drive the growth of the Blincyto market going forward. Leukemia is a cancer that originates in blood-forming tissues such as the bone marrow, resulting in the excessive production of abnormal white blood cells that disrupt normal blood cell function. The increase in leukemia cases is linked to factors including aging populations, environmental exposure, genetic susceptibility, and improvements in diagnostic technologies. Blincyto is used in leukemia treatment as a bispecific T-cell engager that enables the immune system to identify and eliminate leukemia cells, particularly in patients with acute lymphoblastic leukemia (ALL). For instance, in January 2024, according to the American Cancer Society, a US-based non-profit organization, approximately 62,770 new leukemia cases were expected in the United States in 2024, compared with 59,610 cases in 2023. Therefore, the increasing incidence of leukemia is driving the growth of the Blincyto market.

Rising healthcare spending is expected to further propel the growth of the Blincyto market going forward. Healthcare spending refers to total expenditures on healthcare services and products, including personal medical care, public health initiatives, and administrative services. Healthcare expenditure is increasing due to factors such as population growth, aging demographics, higher service costs, a growing burden of chronic diseases, and advancements in medical technology. Increased healthcare spending improves access to advanced cancer therapies such as Blincyto, supporting wider adoption and better patient outcomes. For instance, in May 2024, according to a report published by the Office for National Statistics, a UK-based government agency, healthcare expenditure in the UK reached approximately $363 billion in 2023, reflecting a nominal increase of 5.6% from the previous year, significantly higher than the 0.9% growth recorded in 2022. Therefore, rising healthcare spending is driving the Blincyto market.

Major companies operating in the Blincyto market are concentrating on the development of innovative therapies, including immuno-oncology treatments, to precisely target and destroy cancer cells. Immuno-oncology therapy is a cancer treatment approach that harnesses the body's immune system to recognize, attack, and eliminate cancer cells. For instance, in June 2024, Amgen Inc., a US-based biotechnology company, received approval from the US Food and Drug Administration (FDA) for BLINCYTO (blinatumomab) for the treatment of CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (B-ALL) during the consolidation phase in both adult and pediatric patients aged one month and older, regardless of measurable residual disease (MRD) status. BLINCYTO functions as a bispecific T-cell engager (BiTE), simultaneously binding to CD19 on B-cell malignancies and CD3 on T-cells, thereby directing T-cells to attack and destroy cancer cells.

Major companies operating in the blincyto market are Amgen Inc.

North America was the largest region in the Blincyto market in 2025. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the blincyto market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the blincyto market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

The blincyto market consists of sales of oncology medications, biosimilars, immunotherapy drugs, anti-inflammatory medications and hematology medications. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Blincyto Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses blincyto market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for blincyto ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The blincyto market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Type: Prefilled; Non-Prefilled
• 2) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• 3) By Application: Acute Lymphoblastic Leukemia; Other Hematological Disorders
• 4) By End-User: Hospitals; Clinics; Research Institutions
• Companies Mentioned: Amgen Inc.
• Countries: Australia; India; China; South Korea; Japan; UK; France; Germany; USA; Canada.
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.